Earnings Summary

Unity Biotechnology, Inc.’s net profit jumped 64.08% since last year same period to $-4.34Mn in the Q1 2024. On a quarterly growth basis, Unity Biotechnology, Inc. has generated -189.65% fall in its net profits since last 3-months.

Unity Biotechnology, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.53 - a 26.39% jump from last quarter’s estimates.

Unity Biotechnology, Inc.’s earning per share (EPS) estimates for the current year stand at -0.53.

Unity Biotechnology, Inc.’s earning per share (EPS) jumped 63.16% since last year same period to -0.28 in the Q1 2024. This indicates that the Unity Biotechnology, Inc. has generated 63.16% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Unity Biotechnology, Inc.’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Unity Biotechnology, Inc.’s return on equity (ROE) stands at -0.94.